Andrew
@SingletonNeuro
Followers
934
Following
630
Media
33
Statuses
408
Opinions are my own & do not rep NIA/NIH/HHS
Joined March 2018
Great opportunity!!! @interneurona could you share it between your #LATAM colleagues???
📢 Reminder! The application window to apply for trainee funding through GP2's Underrepresented Populations PhD Program closes 8/31. If you identify as a supervisor from an underrepresented group, apply today
0
1
6
Kimberley has done an amazing job standing up high throughput long read sequencing at CARD….
Today we heard from Kimberley on utilising long nanopore reads to sequence ~4,000 human brain clinical research samples, to further understand Alzheimer’s disease and related dementias #nanoporeconf
0
0
9
love this collaboration!
Our own @C_WSolsberg @halsty and friends from NIH CARD 🧬 identify novel AD loci by leveraging diversity across populations @UCSFmac
1
1
6
Been a great day for publications from the team. @mkoretsky1 and the team great job on showing genetic overlap and in some instances a depletion of genetic risk across and within neurodegenerative diseases.
Genetic risk factor clustering within and across neurodegenerative conditions (such as #Parkinsons, #Alzheimers, #ALS) - from @HamptonLLeonard & colleagues; "Neurodegenerative diseases have more overlapping genetic etiology than previously expected" https://t.co/BXdQ4FUCKi
1
6
13
Dramatic improvement for @nanopore DRS using kits RNA004 vs RNA002 @NUBioE1 a) Human poly-A RNA alignment identity: 2019 (RNA002, 86%), 2022 (RNA002, 89.8%), 2023 (RNA004, 95.6%) b) Human MT poly-A RNA read alignments (2019 vs 2023). Colored lines = base mismatches @AkesonUCSC
6
34
106
Pssst, next GP2 release in ~2 weeks 🤐. Release 5 for Cinco de Mayo (well a few days after).
0
3
7
41 novel targets, network insights and potential tox inferences ... #opensource #openscience ... app here https://t.co/AG2Bi2N3oc. Awesome work from Chelsea X. A. (sensibly twitter averse) to leverage public resource to do this (thx @OpenTargets and other for the APIs)!
nih-card-ndd-smr-home-syboky.streamlit.app
Code for streamlit app to accompany manuscript
0
2
6
New preprint from the team at CARD, nominating novel drug targets for neurodegenerative disease using multi-omic and genetic data. Hoping this is a starting point for community target discovery specifically focused on ADRD. https://t.co/grFO1wSgP8
1
17
44
Funding opportunity! GP2 is co-funding two places for @movedisorder Aspen Course. If you are an early career Movement Disorders Fellow who identifies as belonging to an underrepresented group in #PD research, we encourage you to apply. Deadline is 5/1:
gp2.org
The “Aspen Course” provides a robust scientific content and interaction with the leaders and innovators of the movement disorders field. This makes the Aspen Course an unique opportunity for those…
0
2
1
Great presentation of @mario_cornejo_o in #IIIcongressobrasileironeurogenetica @LARGE_PD @ASAP_Research @arturschuh @nachogenePD
1
4
13
I wrote a blog post for International Women's Day, featuring women in #datascience and #neuroscience at @NIHAging's Center for #Alzheimers and related dementias! https://t.co/nU86As9XCZ
#scicomm #InternationalWomensDay
0
5
15
🎉In case you missed it📢 BLAAC-PD is expanding to six sites, allowing the initiative to continue to grow its partnerships with traditionally underrepresented populations and helping to unlock the genetic architecture of #ParkinsonsDisease.
michaeljfox.org
0
1
4
If you are a doctor or scientist based in Africa, Asia or Latin America interested in getting a master's in clinical neurology or data science via distance learning @ucl or @UMBC, apply for GP2 support! Learn more:
gp2.org
Discover career opportunities across multiple disciplines at GP2, specializing in accelerating Parkinson’s research and innovation.
1
10
11
V Excited about this....Mis-spliced transcripts generate de novo proteins in TDP-43-related ALS/FTD
biorxiv.org
Functional loss of TDP-43, an RNA-binding protein genetically and pathologically linked to ALS and FTD, leads to inclusion of cryptic exons in hundreds of transcripts during disease. Cryptic exons...
0
1
3
📢 Apply to get trained in data science while working with a ton of talented and motivated scientists on Alzheimer’s and related dementias research at #CARD ! 📢 🤩
The @NIH Center for Alzheimer’s and Related Dementias (CARD) Master’s Program application portal is now open! Interested in pursuing a master’s degree from @UMBC and a career in #DataScience? Apply by May 1: https://t.co/yVYXVwxNnv
#CARDMastersProgram
0
1
4
A nice thread here:
BREAKING NEWS: New #Alzheimer drug #Lecanemab slows cognitive decline (18-month change in CDR-SB) by 27%, drastically lowers brain amyloid load by 59 centiloids to 23 (below PET amyloid positivity)! NEJM paper: https://t.co/XYaxRlkH48
https://t.co/29YFLvyS8t
#CTAD
0
2
7
It’s quafftide somewhere. Here in fact.
Word of the day is ‘quafftide’(16th century): a one-word announcement that it’s time for a drink.
0
0
2
https://t.co/teK9HJWFny
@ASAP_Research says GP2 release 3 is now official. Shout outs to the team for sharing > 14K samples! Nice work in particular from @HamptonLLeonard @KristinSLevine @mbmakarious #DanV and #MatK on the blog post and README. READMEs, always important 🧐.
gp2.org
In October 2022, GP2 announced the third data release on the Terra platform in collaboration with AMP® PD. This release is packed full of new data and resources and includes almost twice as many…
1
6
13
a fantastic resource....really excited to support this work through CARD at the NIH IRP. Next comes the exciting part...
New batch of engineered iPSC lines from JAX/iNDI, including much-requested APOE variants! Isogenic sets of APOE2, 3, 4, and Christchurch variants, plus revertant controls, all deeply QC'd and available with a clickable online MTA. https://t.co/twDD1gidqM
0
0
4
Anyone dug around in their GP2 tier2 buckets lately? If so, how's new data in release 3 (its live already in your workspace 😈). R3 is official very soon (couple weeks), keep your eyes on the GP2 blog. Epic teamwork from too many (some on this call)! #OpenScience
1
4
10